Nyika D Kruyt

Nyika D Kruyt

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2021 in JAMA Neurology
Verified
Journal Article
Open access
PDF file
TNT. Truc My Nguyen
T. Truc My Nguyen
IWIdo R. van Den Wijngaard
Ido R. van Den Wijngaard
JBJan Bosch
Jan Bosch
EBEduard van Belle
Eduard van Belle
EZErik W. van Zwet
Erik W. van Zwet
NKNyika D Kruyt
Nyika D Kruyt
In acute ischemic stroke, clinical efficacy of intravenous thrombolysis (IVT) and endovascular thrombectomy (EVT) is highly time dependent.1-3 Endovascular thrombectomy can only be given to a subset of patients with a symptomatic large anterior vessel occlusion (sLAVO), constituting 4.9% to 14.5% of all patients with suspected stroke.4,5 Contrary to IVT, which is available in most primary stroke centers (PSCs), EVT is an elaborate treatment and, therefore, restricted to comprehensive stroke centers (CSCs) with EVT facilities. Because sLAVO cannot be reliably identified in the ambulance, patients suspected of acute stroke are often transferred to the nearest hospital (often a PSC) to start IVT as soon as possible. For patients with sLAVO, this routing leads to a median of 60 to 109 minutes’ delay due to interhospital transfers, with associated worse functional outcomes.6,7 Prehospital identification of patients with sLAVO enabling direct allocation to a CSC would greatly reduce delays to EVT treatment and improve clinical outcomes.

14 December 2021 in Stroke
Verified
Journal Article
Open access
PDF file
MAMariam Ali
Mariam Ali
HOHendrikus J.A. van Os
Hendrikus J.A. van Os
NWNelleke van der Weerd
Nelleke van der Weerd
JSJan Schoones
Jan Schoones
MHMartijn W. Heymans
Martijn W. Heymans
MWMarieke J.H. Wermer
Marieke J.H. Wermer
Background and Purpose: Women have worse outcomes than men after stroke. Differences in presentation may lead to misdiagnosis and, in part, explain these disparities. We investigated whether there are sex differences in clinical presentation of acute stroke or transient ischemic attack. Methods: We conducted a systematic review and meta-analysis according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement. Inclusion criteria were (1) cohort, cross-sectional, case-control, or randomized controlled trial design; (2) admission for (suspicion of) ischemic or hemorrhagic stroke or transient ischemic attack; and (3) comparisons possible between sexes in ≥1 nonfocal or focal acute stroke symptom(s). A random-effects model was used for our analyses. We performed sensitivity and subanalyses to help explain heterogeneity and used the Newcastle-Ottawa Scale to assess bias. Results: We included 60 studies (n=582 844; 50% women). In women, headache (pooled odds ratio [OR], 1.24 [95% CI, 1.11–1.39]; I 2 =75.2%; 30 studies) occurred more frequently than in men with any type of stroke, as well as changes in consciousness/mental status (OR, 1.38 [95% CI, 1.19–1.61]; I 2 =95.0%; 17 studies) and coma/stupor (OR, 1.39 [95% CI, 1.25–1.55]; I 2 =27.0%; 13 studies). Aspecific or other neurological symptoms (nonrotatory dizziness and non-neurological symptoms) occurred less frequently in women (OR, 0.96 [95% CI, 0.94–0.97]; I 2 =0.1%; 5 studies). Overall, the presence of focal symptoms was not associated with sex (pooled OR, 1.03) although dysarthria (OR, 1.14 [95% CI, 1.04–1.24]; I 2 =48.6%; 11 studies) and vertigo (OR, 1.23 [95% CI, 1.13–1.34]; I 2 =44.0%; 8 studies) occurred more frequently, whereas symptoms of paresis/hemiparesis (OR, 0.73 [95% CI, 0.54–0.97]; I 2 =72.6%; 7 studies) and focal visual disturbances (OR, 0.83 [95% CI, 0.70–0.99]; I 2 =62.8%; 16 studies) occurred less frequently in women compared with men with any type of stroke. Most studies contained possible sources of bias. Conclusions: There may be substantive differences in nonfocal and focal stroke symptoms between men and women presenting with acute stroke or transient ischemic attack, but sufficiently high-quality studies are lacking. More studies are needed to address this because sex differences in presentation may lead to misdiagnosis and undertreatment.

1 August 2020 in Autoimmunity Reviews
Verified
Journal Article
Open access
SDSander J. Deijns
Sander J. Deijns
JBJasper C.A. Broen
Jasper C.A. Broen
NKNyika D Kruyt
Nyika D Kruyt
CSChris D. Schubart
Chris D. Schubart
LALaura ANDREOLI
Laura ANDREOLI
MLMaarten Limper
Maarten Limper
The aim of this narrative review is to provide an overview of the literature on the possible immunologic pathophysiology of psychiatric manifestations of neuropsychiatric systemic lupus erythematosus (NPSLE). A systematic search on PubMed was conducted. English studies with full text availability that investigated the correlation between blood-brain barrier (BBB) dysfunction, intrathecal synthesis of antibodies, antibodies, cytokines, chemokines, metalloproteinases, complement and psychiatric NPSLE manifestations in adults were included. Both transient BBB-dysfunction with consequent access of antibodies to the cerebrospinal fluid (CSF) and intrathecal synthesis of antibodies could occur in psychiatric NPSLE. Anti-phospholipid antibodies, anti-NMDA antibodies and anti-ribosomal protein p antibodies seem to mediate concentration dependent neuronal dysfunction. Interferon-α may induce microglial engulfment of neurons, direct neuronal damage and production of cytokines and chemokines in psychiatric NPSLE. Several cytokines, chemokines and matrix metalloproteinase-9 may contribute to the pathophysiology of psychiatric NPSLE by attracting and activating Th1-cells and B-cells. This potential pathophysiology may help understand NPSLE and may have implications for the diagnostic management and therapy of psychiatric NPSLE. However, the presented pathophysiological model is based on correlations between potential immunologic etiologies and psychiatric NPSLE that remain questionable. More research on this topic is necessary to further elucidate the pathophysiology of NPSLE.

Verified
Journal Article
Open access
PDF file
TNT. Truc My Nguyen
T. Truc My Nguyen
MBM. Leontien van der Bent
M. Leontien van der Bent
MWMarieke J. H. Wermer
Marieke J. H. Wermer
IWIdo R. van Den Wijngaard
Ido R. van Den Wijngaard
EZErik W. van Zwet
Erik W. van Zwet
ANAnne Yaël Nossent
Anne Yaël Nossent
Early blood biomarkers to diagnose acute stroke could drastically reduce treatment delays. We investigated whether circulating small non-coding RNAs can serve as biomarkers to distinguish between acute ischemic stroke (IS), intracerebral hemorrhage (ICH) and stroke mimics (SM). In an ongoing observational cohort study, we performed small RNA-sequencing in plasma obtained from a discovery cohort of 26 patients (9 IS, 8 ICH and 9 SM) presented to the emergency department within 6 h of symptom onset. We validated our results in an independent dataset of 20 IS patients and 20 healthy controls. ICH plasma had the highest abundance of ribosomal and tRNA-derived fragments, while microRNAs were most abundant in plasma of IS patients. Combinations of four to five tRNAs yielded diagnostic accuracies (areas under the receiver operating characteristics curve) up to 0.986 (ICH vs. IS and SM) in the discovery cohort. Validation of the IS and SM models in the independent dataset yielded diagnostic accuracies of 0.870 and 0.885 to distinguish IS from healthy controls. Thus, we identified tRNA-derived fragments as a promising novel class of biomarkers to distinguish between acute IS, ICH and SM, as well as healthy controls.

20 October 2018 in Trials
Verified
Journal Article
Open access
PDF file
IMIshita P. Miah
Ishita P. Miah
DHDana C. Holl
Dana C. Holl
WPWilco C. Peul
Wilco C. Peul
RWRobert Walchenbach
Robert Walchenbach
NKNyika D Kruyt
Nyika D Kruyt
NGNiels A. Van Der Gaag
Niels A. Van Der Gaag
Chronic subdural haematoma (CSDH) is a common neurological disease with a rapidly rising incidence due to increasing age and widespread use of anticoagulants. Surgical intervention by burr-hole craniotomy (BHC) is the current standard practice for symptomatic patients, but associated with complications, a recurrence rate of up to 30% and increased mortality. Dexamethasone (DXM) therapy is, therefore, used as a non-surgical alternative but considered to achieve a lower success rate. Furthermore, the benefit of DXM therapy appears much more deliberate than the immediate relief from BHC. Lack of evidence and clinical equipoise among caregivers prompts the need for a head-to-head randomised controlled trial. The objective of this study is to compare the effect of primary DXM therapy versus primary BHC on functional outcome and cost-effectiveness in symptomatic patients with CSDH. This study is a prospective, multicentre, randomised controlled trial (RCT). Consecutive patients with a CSDH with a Markwalder Grading Scale (MGS) grade 1 to 3 will be randomised to treatment with DXM or BHC. The DXM treatment scheme will be 16 mg DXM per day (8 mg twice daily, days 1 to 4) which is then halved every 3 days until a dosage of 0.5 mg a day on day 19 and stopped on day 20. If the treatment response is insufficient (i.e. persistent or progressive symptomatology due to insufficient haematoma resolution), additional surgery can be performed. The primary outcomes are the functional outcome by means of the modified Rankin Scale (mRS) score at 3 months and cost-effectiveness at 12 months. Secondary outcomes are quality of life at 3 and 12 months using the Short Form Health Survey (SF-36) and Quality of Life after Brain Injury Overall Scale (QOLIBRI), haematoma thickness after 2 weeks on follow–up computed tomography (CT), haematoma recurrence during the first 12 months, complications and drug-related adverse events, failure of therapy within 12 months after randomisation and requiring intervention, mortality during the first 3 and 12 months, duration of hospital stay and overall healthcare and productivity costs. To test non-inferiority of DXM therapy compared to BHC, 210 patients in each treatment arm are required (assumed adjusted common odds ratio DXM compared to BHC 1.15, limit for inferiority < 0.9). The aim is to include a total of 420 patients in 3 years with an enrolment rate of 60%. The present study should demonstrate whether treatment with DXM is as effective as BHC on functional outcome, at lower costs. EUCTR 2015-001563-39 . Date of registration: 29 March 2015.

16 May 2024 in The Lancet Neurology
Verified
Journal Article
Closed access
TZThomas P Zonneveld
Thomas P Zonneveld
SVSarah E Vermeer
Sarah E Vermeer
EZErik W van Zwet
Erik W van Zwet
AGAdrien E D Groot
Adrien E D Groot
AAAle Algra
Ale Algra
NKNyika D Kruyt
Nyika D Kruyt